利伐沙班治疗6周与3个月对症状性孤立性远端深静脉血栓患者的随机对照试验
该随机、双盲、安慰剂对照试验在28家静脉血栓栓塞专科门诊纳入402例症状性孤立性远端DVT成人患者,所有患者先接受标准剂量利伐沙班6周,随后随机接受额外6周利伐沙班20 mg每日一次(200例)或安慰剂(202例),随访24个月。主要疗效终点(复发性VTE复合终点)在利伐沙班组发生23例(11%),安慰剂组39例(19%),相对风险0.59(95%CI 0.36-0.95;P=0.03),需治疗人数13(95%CI 7-126)。复发性孤立性远端DVT在利伐沙班组16例(8%),安慰剂组31例(15%)(P=0.02);近端DVT或肺栓塞在利伐沙班组7例(3%),安慰剂组8例(4%)(P=0.80)。无大出血事件。结论认为,对于6周治疗过程平稳的孤立性远端DVT患者,额外6周利伐沙班治疗可降低2年内复发性VTE风险,主要降低复发性孤立性远端DVT,且不增加出血风险。
要点
- 症状性孤立性远端DVT患者在接受标准剂量利伐沙班6周后,继续利伐沙班20 mg每日一次6周 vs 安慰剂,主要疗效终点(复发性VTE)11% vs 19%(RR 0.59,95%CI 0.36-0.95;P=0.03;NNT 13,95%CI 7-126)。
- 复发性孤立性远端DVT在利伐沙班组8% vs 安慰剂组15%(P=0.02)。
- 近端DVT或肺栓塞在利伐沙班组3% vs 安慰剂组4%(P=0.80),无显著差异。
- 两组均无大出血事件。
- 随访24个月,额外6周利伐沙班降低复发性VTE风险,主要降低复发性孤立性远端DVT。
适用人群与场景
- 年龄≥18岁的症状性孤立性远端深静脉血栓(DVT)成人患者。
- 患者在入选前已接受标准剂量利伐沙班治疗6周,且治疗过程平稳(uneventful)。
诊断标准与关键阈值
- 主要疗效终点:随机化后随访期间复发性静脉血栓栓塞,定义为孤立性远端DVT进展、复发性孤立性远端DVT、近端DVT、症状性肺栓塞或致死性肺栓塞的复合终点。
- 主要安全终点:随机化后至利伐沙班或安慰剂末次给药后2天内的大出血。
处置流程与药物剂量
- 所有患者先接受标准剂量利伐沙班治疗6周。
- 6周后随机接受额外6周利伐沙班20 mg每日一次口服或安慰剂。
- 随访24个月(从研究入选算起)。
研究设计与关键结果
- 研究设计:随机、双盲、安慰剂对照临床试验;28家静脉血栓栓塞专科门诊;402例成人患者。
- 分组:额外利伐沙班组200例,安慰剂组202例;孤立性远端DVT为无诱因者分别为81例(40%)和86例(43%)。
- 主要疗效终点:利伐沙班组23例(11%) vs 安慰剂组39例(19%)(相对风险0.59,95%CI 0.36-0.95;P=0.03;NNT 13,95%CI 7-126)。
- 复发性孤立性远端DVT:利伐沙班组16例(8%) vs 安慰剂组31例(15%)(P=0.02)。
- 近端DVT或肺栓塞:利伐沙班组7例(3%) vs 安慰剂组8例(4%)(P=0.80)。
- 大出血事件:无。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于已完成6周标准剂量利伐沙班治疗且过程平稳的症状性孤立性远端DVT患者,作者认为额外6周利伐沙班20 mg每日一次可降低2年内复发性VTE风险,主要降低复发性孤立性远端DVT,且不增加出血风险。
指南或共识出处
- 原文为随机对照试验,标题:Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial;试验注册号:EudraCT 2016-000958-36;ClinicalTrials.gov NCT02722447。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare two different treatment durations of rivaroxaban in patients with symptomatic isolated distal deep vein thrombosis (DVT).
DESIGN: Randomised, double blind, placebo controlled clinical trial.
SETTING: 28 outpatient clinics specialising in venous thromboembolism.
PARTICIPANTS: 402 adults (≥18 years) with symptomatic isolated distal DVT.
INTERVENTIONS: After receiving standard dose rivaroxaban for six weeks, participants were randomly assigned to receive rivaroxaban 20 mg or placebo once daily for an additional six weeks. Follow-up was for 24 months from study inclusion.
MAIN OUTCOMES MEASURES: The primary efficacy outcome was recurrent venous thromboembolism during follow-up after randomisation, defined as the composite of progression of isolated distal DVT, recurrent isolated distal DVT, proximal DVT, symptomatic pulmonary embolism, or fatal pulmonary embolism. The primary safety outcome was major bleeding after randomisation until two days from the last dose of rivaroxaban or placebo. An independent committee adjudicated the outcomes.
RESULTS: 200 adults were randomised to receive additional rivaroxaban treatment and 202 to receive placebo. Isolated distal DVT was unprovoked in 81 (40%) and 86 (43%) patients, respectively. The primary efficacy outcome occurred in 23 (11%) patients in the rivaroxaban arm and 39 (19%) in the placebo arm (relative risk 0.59, 95% confidence interval 0.36 to 0.95; P=0.03, number needed to treat 13, 95% confidence interval 7 to 126). Recurrent isolated distal DVT occurred in 16 (8%) patients in the rivaroxaban arm and 31 (15%) in the placebo arm (P=0.02). Proximal DVT or pulmonary embolism occurred in seven (3%) patients in the rivaroxaban arm and eight (4%) in the placebo arm (P=0.80). No major bleeding events occurred.
CONCLUSIONS: Rivaroxaban administered for six additional weeks in patients with isolated distal DVT who had an uneventful six week treatment course reduces the risk of recurrent venous thromboembolism, mainly recurrent isolated distal DVT, over a two year follow-up without increasing the risk of haemorrhage.
TRIAL REGISTRATION: EudraCT 2016-000958-36; ClinicalTrials.gov NCT02722447.
参考来源
- Ageno W, Bertù L, Bucherini E, et al. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ. 2022. PMID: 36520715. doi:10.1136/bmj-2022-072623
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。